Dynavax：HEPLISAV
HEPLISAV
HEPLISAV-BisindicatedforpreventionofinfectioncausedbyallknownsubtypesofhepatitisBvirusinadults18yearsofageandolder.。其他文章還包含有：「About|CoreValues」、「DVAX-DynavaxTechnologiesCorporation」、「DynavaxReportsFirstQuarter2024FinancialResultsand...」、「DynavaxTechnologies」、「DynavaxTechnologiesCorporation(DVAX)StockPrice」、「DynavaxTechnologiesCorporation(DVAX)股價、新聞」、「DynavaxTe...
查看更多 離開網站
About | Core Values
https://www.dynavax.com
We are dedicated to developing and commercializing novel vaccines to help protect the world against infectious diseases.
DVAX-Dynavax Technologies Corporation
https://www.moneydj.com
Dynavax Technologies Corporation(DVAX.US)成立於1996年，前身為「Double Helix Corporation」，同年9月更為現名，總部位於加州柏克來，主要在美國從事新型疫苗與治療學之發現 ...
Dynavax Reports First Quarter 2024 Financial Results and ...
https://www.prnewswire.com
Share this article · Total revenues for the first quarter of 2024 were $50.8 million, compared to $46.9 million for the first quarter of 2023.
Dynavax Technologies
https://tw.linkedin.com
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against ...
Dynavax Technologies Corporation (DVAX) Stock Price
https://finance.yahoo.com
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
Dynavax Technologies Corporation (DVAX) 股價、新聞
https://hk.finance.yahoo.com
查看最新的Dynavax Technologies Corporation (DVAX) 股票報價、記錄、新聞及其他重要資訊，助你賣買股票及投資。
Dynavax Technologies | Toll
https://www.dynavax.com
Dynavax Technologies is focused on leveraging the power of the body's innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.
Investor Relations
http://investors.dynavax.com
Dynavax is a commercial-stage biopharmaceutical company built on the foundation of our significant experience and expertise in vaccine development and ...
高端疫苗使用美國Dynavax新型佐劑之新冠肺炎(COVID
https://www.medigenvac.com
台灣台北市和美國加州：高端疫苗的新冠肺炎疫苗結合美國國衛院基因重組棘蛋白抗原(S-2P)與美國Dynavax公司（Nasdaq：DVAX）之新型佐劑，上月獲衛福部人體一 ...